ES2386082T3 - Uso de inhibidores PI3K y AKT para inducir la expresión de FOXP3 y generar células T reguladoras - Google Patents

Uso de inhibidores PI3K y AKT para inducir la expresión de FOXP3 y generar células T reguladoras Download PDF

Info

Publication number: ES2386082T3
Authority: ES; Spain
Prior art keywords: cells; pi3k; foxp3; cell; tcr
Prior art date: 2006-12-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07848526T

Other languages

English (en)

Spanish (es)

Inventor

Matthias Michael MERKENSCHLAGER

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Medical Research Council

Original Assignee

Medical Research Council

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-14

Filing date

2007-12-13

Publication date

2012-08-08

2006-12-14 Priority claimed from GB0624999A external-priority patent/GB0624999D0/en

2007-04-19 Priority claimed from GB0707609A external-priority patent/GB0707609D0/en

2007-12-13 Application filed by Medical Research Council filed Critical Medical Research Council

2007-12-13 Priority claimed from PCT/GB2007/004784 external-priority patent/WO2008071974A2/en

2012-08-08 Application granted granted Critical

2012-08-08 Publication of ES2386082T3 publication Critical patent/ES2386082T3/es

Status Active legal-status Critical Current

2027-12-13 Anticipated expiration legal-status Critical

Links

108091007960 PI3Ks Proteins 0.000 title claims abstract description 190
230000014509 gene expression Effects 0.000 title claims abstract description 144
210000003289 regulatory T cell Anatomy 0.000 title claims description 117
239000012828 PI3K inhibitor Substances 0.000 title claims description 72
102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 title abstract 3
239000003197 protein kinase B inhibitor Substances 0.000 title description 7
102100027581 Forkhead box protein P3 Human genes 0.000 title description 2
101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 title description 2
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 230
230000000638 stimulation Effects 0.000 claims abstract description 91
230000011664 signaling Effects 0.000 claims abstract description 83
230000005764 inhibitory process Effects 0.000 claims abstract description 76
238000000034 method Methods 0.000 claims abstract description 72
238000000338 in vitro Methods 0.000 claims abstract description 35
230000002401 inhibitory effect Effects 0.000 claims abstract description 16
230000001939 inductive effect Effects 0.000 claims abstract description 15
230000004936 stimulating effect Effects 0.000 claims abstract description 9
210000004027 cell Anatomy 0.000 claims description 179
108091008874 T cell receptors Proteins 0.000 claims description 169
102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 165
239000003112 inhibitor Substances 0.000 claims description 114
230000006698 induction Effects 0.000 claims description 97
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 95
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 66
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 66
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 61
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 59
230000000694 effects Effects 0.000 claims description 50
108010044467 Isoenzymes Proteins 0.000 claims description 31
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims description 24
102000038030 PI3Ks Human genes 0.000 claims description 23
230000004044 response Effects 0.000 claims description 23
CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 22
239000012823 PI3K/mTOR inhibitor Substances 0.000 claims description 20
230000004069 differentiation Effects 0.000 claims description 14
230000009711 regulatory function Effects 0.000 claims description 14
238000001727 in vivo Methods 0.000 claims description 11
230000037361 pathway Effects 0.000 claims description 6
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 165
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 165
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 72
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 70
229960002930 sirolimus Drugs 0.000 description 70
230000004913 activation Effects 0.000 description 47
108091008611 Protein Kinase B Proteins 0.000 description 40
238000011282 treatment Methods 0.000 description 38
102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 27
101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 27
230000026731 phosphorylation Effects 0.000 description 24
238000006366 phosphorylation reaction Methods 0.000 description 24
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 21
101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 21
102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 21
102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 21
101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 21
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 21
230000033228 biological regulation Effects 0.000 description 18
150000001875 compounds Chemical class 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 18
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 17
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 17
101001024630 Drosophila melanogaster RNA cytidine acetyltransferase Proteins 0.000 description 16
101000652705 Drosophila melanogaster Transcription initiation factor TFIID subunit 4 Proteins 0.000 description 16
101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 16
101000996915 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleoporin NSP1 Proteins 0.000 description 16
102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 16
239000000427 antigen Substances 0.000 description 16
102000036639 antigens Human genes 0.000 description 16
108091007433 antigens Proteins 0.000 description 16
102000004169 proteins and genes Human genes 0.000 description 16
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 15
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 15
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 15
230000006870 function Effects 0.000 description 15
210000004698 lymphocyte Anatomy 0.000 description 14
238000012546 transfer Methods 0.000 description 14
238000013459 approach Methods 0.000 description 13
238000002474 experimental method Methods 0.000 description 13
238000012360 testing method Methods 0.000 description 13
230000032823 cell division Effects 0.000 description 12
238000010212 intracellular staining Methods 0.000 description 12
208000023275 Autoimmune disease Diseases 0.000 description 11
230000002950 deficient Effects 0.000 description 11
230000028993 immune response Effects 0.000 description 11
230000002093 peripheral effect Effects 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 10
108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 10
102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 10
101710125691 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 10
108091000080 Phosphotransferase Proteins 0.000 description 10
230000008901 benefit Effects 0.000 description 10
210000003162 effector t lymphocyte Anatomy 0.000 description 10
102000020233 phosphotransferase Human genes 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
230000005784 autoimmunity Effects 0.000 description 9
239000012636 effector Substances 0.000 description 9
102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 8
101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 8
FCKJZIRDZMVDEM-UHFFFAOYSA-N N-(7,8-dimethoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene)pyridine-3-carboxamide Chemical compound COC1=C(C2=NC(=NC(=O)C3=CN=CC=C3)N4CCNC4=C2C=C1)OC FCKJZIRDZMVDEM-UHFFFAOYSA-N 0.000 description 8
150000003384 small molecules Chemical class 0.000 description 8
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 7
108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 7
210000003630 histaminocyte Anatomy 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000002441 reversible effect Effects 0.000 description 7
210000001541 thymus gland Anatomy 0.000 description 7
230000009261 transgenic effect Effects 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
210000000612 antigen-presenting cell Anatomy 0.000 description 6
230000000975 bioactive effect Effects 0.000 description 6
206010009887 colitis Diseases 0.000 description 6
238000012423 maintenance Methods 0.000 description 6
230000007170 pathology Effects 0.000 description 6
238000003753 real-time PCR Methods 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
101150076297 ywhaz gene Proteins 0.000 description 6
102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 5
101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
108010029485 Protein Isoforms Proteins 0.000 description 5
102000001708 Protein Isoforms Human genes 0.000 description 5
102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 5
101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 5
230000006044 T cell activation Effects 0.000 description 5
102000040945 Transcription factor Human genes 0.000 description 5
108091023040 Transcription factor Proteins 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
230000036039 immunity Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
239000003446 ligand Substances 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
230000003472 neutralizing effect Effects 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
IWCQHVUQEFDRIW-UHFFFAOYSA-N 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(cc2)-c2[nH]c3cc4ncnc4cc3nc2-c2ccccc2)CC1 IWCQHVUQEFDRIW-UHFFFAOYSA-N 0.000 description 4
101150107888 AKT2 gene Proteins 0.000 description 4
102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 4
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 4
108010074338 Lymphokines Proteins 0.000 description 4
102000008072 Lymphokines Human genes 0.000 description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
230000009471 action Effects 0.000 description 4
101150045355 akt1 gene Proteins 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
230000003832 immune regulation Effects 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
238000003119 immunoblot Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000000411 inducer Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
229940124302 mTOR inhibitor Drugs 0.000 description 4
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
230000008685 targeting Effects 0.000 description 4
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 4
FWYYZGLCNUZWPF-UHFFFAOYSA-N 8-(2-methylphenoxy)-2-(4-morpholinyl)-1H-quinolin-4-one Chemical compound CC1=CC=CC=C1OC1=CC=CC2=C1NC(N1CCOCC1)=CC2=O FWYYZGLCNUZWPF-UHFFFAOYSA-N 0.000 description 3
102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
229940126638 Akt inhibitor Drugs 0.000 description 3
101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 3
101000761737 Homo sapiens Ubiquitin-conjugating enzyme E2 L3 Proteins 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
108010002335 Interleukin-9 Proteins 0.000 description 3
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 3
108010070047 Notch Receptors Proteins 0.000 description 3
102000005650 Notch Receptors Human genes 0.000 description 3
-1 PI-103 compound Chemical class 0.000 description 3
108090000315 Protein Kinase C Proteins 0.000 description 3
102000003923 Protein Kinase C Human genes 0.000 description 3
101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
108010000605 Ribosomal Proteins Proteins 0.000 description 3
102000002278 Ribosomal Proteins Human genes 0.000 description 3
201000001322 T cell deficiency Diseases 0.000 description 3
108091005735 TGF-beta receptors Proteins 0.000 description 3
102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 3
102100024861 Ubiquitin-conjugating enzyme E2 L3 Human genes 0.000 description 3
239000012190 activator Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
230000005754 cellular signaling Effects 0.000 description 3
230000001010 compromised effect Effects 0.000 description 3
230000004940 costimulation Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000003958 hematopoietic stem cell Anatomy 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
229940043355 kinase inhibitor Drugs 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000002501 natural regulatory T cell Anatomy 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
239000003757 phosphotransferase inhibitor Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
NGAGMBNBKCDCDJ-UHFFFAOYSA-N 8-phenyl-2-(1-piperazinyl)-1-benzopyran-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCNCC3)OC2=C1C1=CC=CC=C1 NGAGMBNBKCDCDJ-UHFFFAOYSA-N 0.000 description 2
102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 2
230000007730 Akt signaling Effects 0.000 description 2
101150051155 Akt3 gene Proteins 0.000 description 2
229930105110 Cyclosporin A Natural products 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 2
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
108090000852 Forkhead Transcription Factors Proteins 0.000 description 2
102000004315 Forkhead Transcription Factors Human genes 0.000 description 2
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 2
101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 2
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000003746 Insulin Receptor Human genes 0.000 description 2
108010001127 Insulin Receptor Proteins 0.000 description 2
102100025087 Insulin receptor substrate 1 Human genes 0.000 description 2
108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
101150097381 Mtor gene Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229940124780 PI3K delta inhibitor Drugs 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
102000003861 Ribosomal protein S6 Human genes 0.000 description 2
108090000221 Ribosomal protein S6 Proteins 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 2
108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
239000000654 additive Substances 0.000 description 2
229940125528 allosteric inhibitor Drugs 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
239000011436 cob Substances 0.000 description 2
108091008034 costimulatory receptors Proteins 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000002900 effect on cell Effects 0.000 description 2
229960005167 everolimus Drugs 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
QTHCAAFKVUWAFI-OCKHKDLRSA-N n-[(z)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-n,2-dimethyl-5-nitrobenzenesulfonamide Chemical compound C=1N=C2C=CC(Br)=CN2C=1\C=N/N(C)S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1C QTHCAAFKVUWAFI-OCKHKDLRSA-N 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
244000052769 pathogen Species 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
230000003393 splenic effect Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
229960000235 temsirolimus Drugs 0.000 description 2
108091008023 transcriptional regulators Proteins 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
102100034134 Activin receptor type-1B Human genes 0.000 description 1
102100034135 Activin receptor type-1C Human genes 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
101100278885 Arabidopsis thaliana E2FE gene Proteins 0.000 description 1
101100028391 Arabidopsis thaliana PI4KB1 gene Proteins 0.000 description 1
102100021738 Beta-adrenergic receptor kinase 1 Human genes 0.000 description 1
102000004631 Calcineurin Human genes 0.000 description 1
108010042955 Calcineurin Proteins 0.000 description 1
108091007962 Class I PI3K catalytic Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102100030011 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 1
101000751445 Homo sapiens Beta-adrenergic receptor kinase 1 Proteins 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 1
101000770770 Homo sapiens Serine/threonine-protein kinase WNK1 Proteins 0.000 description 1
102100026818 Inhibin beta E chain Human genes 0.000 description 1
108030003815 Inositol 3-kinases Proteins 0.000 description 1
102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
102000019145 JUN kinase activity proteins Human genes 0.000 description 1
102100033467 L-selectin Human genes 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
101150018665 MAPK3 gene Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101150024075 Mapk1 gene Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100087591 Mus musculus Rictor gene Proteins 0.000 description 1
101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
101710156940 RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
101710103995 RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 1
102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
102000007374 Smad Proteins Human genes 0.000 description 1
108010007945 Smad Proteins Proteins 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
238000002679 ablation Methods 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
239000000488 activin Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000002439 beta secretase inhibitor Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229940046731 calcineurin inhibitors Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
101150113535 chek1 gene Proteins 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000002224 dissection Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000005937 nuclear translocation Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229940127017 oral antidiabetic Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000009038 pharmacological inhibition Effects 0.000 description 1
125000001095 phosphatidyl group Chemical group 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
108010056274 polo-like kinase 1 Proteins 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
102000034285 signal transducing proteins Human genes 0.000 description 1
108091006024 signal transducing proteins Proteins 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
102000009076 src-Family Kinases Human genes 0.000 description 1
108010087686 src-Family Kinases Proteins 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000023750 transforming growth factor beta production Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000009752 translational inhibition Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Landscapes

Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES07848526T 2006-12-14 2007-12-13 Uso de inhibidores PI3K y AKT para inducir la expresión de FOXP3 y generar células T reguladoras Active ES2386082T3 (es)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US87468306P	2006-12-14	2006-12-14
GB0624999		2006-12-14
US874683P		2006-12-14
GB0624999A GB0624999D0 (en)	2006-12-14	2006-12-14	Methods and users
US91244807P	2007-04-18	2007-04-18
US912448P		2007-04-18
GB0707609A GB0707609D0 (en)	2007-04-19	2007-04-19	Methods and uses
GB0707609		2007-04-19
PCT/GB2007/004784 WO2008071974A2 (en)	2006-12-14	2007-12-13	Use of pi3k m-tor and akt inhibitors to induce f0xp3 expression and generate regulatory t cells

Publications (1)

Publication Number	Publication Date
ES2386082T3 true ES2386082T3 (es)	2012-08-08

Family

ID=46060807

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES07848526T Active ES2386082T3 (es)	2006-12-14	2007-12-13	Uso de inhibidores PI3K y AKT para inducir la expresión de FOXP3 y generar células T reguladoras

Country Status (3)

Country	Link
AT (1)	ATE555193T1 (da)
DK (1)	DK2094837T3 (da)
ES (1)	ES2386082T3 (da)

2007
- 2007-12-13 ES ES07848526T patent/ES2386082T3/es active Active
- 2007-12-13 AT AT07848526T patent/ATE555193T1/de active
- 2007-12-13 DK DK07848526.5T patent/DK2094837T3/da active

Also Published As

Publication number	Publication date
ATE555193T1 (de)	2012-05-15
DK2094837T3 (da)	2012-07-16

Publication	Publication Date	Title
US9314485B2 (en)	2016-04-19	Use of PI3K M-TOR and AKT inhibitors to induce FOXP3 expression and generate regulatory T cells
Pollizzi et al.	2014	Integrating canonical and metabolic signalling programmes in the regulation of T cell responses
Park et al.	2013	TSC1 regulates the balance between effector and regulatory T cells
US9532997B2 (en)	2017-01-03	Compositions and methods for promoting intestinal stem cell function
US20090257988A1 (en)	2009-10-15	Methods and compositions for accelerating the generation of regulatory t cells ex vivo
EP3521419B1 (en)	2026-03-18	Method for producing brown adipocytes and composition
Lim et al.	2007	Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells
Scheinert et al.	2016	Therapeutic effects of stress-programmed lymphocytes transferred to chronically stressed mice
JP2022527338A (ja)	2022-06-01	多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法
ES2386082T3 (es)	2012-08-08	Uso de inhibidores PI3K y AKT para inducir la expresión de FOXP3 y generar células T reguladoras
US8951796B2 (en)	2015-02-10	Methods and compositions for expanding and stabilizing natural regulatory T cells
Haubert et al.	2012	Vav1 GEF activity is required for T cell mediated allograft rejection
Watt et al.	2023	Rewiring of the TCR signalosome in natural intestinal Intraepithelial T lymphocytes drives non-deletional tolerance
US20250025500A1 (en)	2025-01-23	Phosphatase inhibitors as nk cells modulators for the treatment of cancer
Martins	2021	Overcoming Self-Reactivity in Type 1 Diabetes via Modulation of Immune Cell Metabolism
Chandrasekaran	2010	Phospholipase D Signaling in T Cells
Darden	2022	Regulation of Islet Cell Differentiation and Function by Calcineurin/NFATc2 Signaling and Applications for Islet Cell Transplantation
Kato et al.	2016	Roles of mechanistic target of rapamycin in the adaptive and innate immune systems
Shrestha	2016	PTEN signaling in regulatory T cells and inflammatory disease
Pai	2016	Modulators of Th17/Treg Differentiation and Function
Chiappetta	2018	The Role of Glycolysis in shaping the Autoimmune Potential of Myelin-Reactive T Cells in the Course of Experimental Autoimmune Encephalomyelitis
Heikamp	2015	mTOR REGULATES CD4 AND CD8 EFFECTOR T CELL DIFFERENTIATION VIA SERUM-AND GLUCOCORTICOID-REGULATED KINASE 1 (SGK1)
Bettencourt	2020	The role of amino acid metabolism in the regulation of T cell fate
Colombetti	2004	Dissecting the Molecular Mechanisms Regulating Proliferation, Antigen Responsiveness, and Differentiation of CD4+ T Lymphocytes: A Central Role for the Mammalian Target of Rapamycin (mTor)
Baum	2017	The Role of Interleukin-21 in the Chronic Rejection of Transplant Allografts and the Development of Type 1 Diabetes